Você procurou por: hyperlactataemia (Inglês - Maltês)

mild isolated neutropenia and hyperlactataemia was observed, which spontaneously disappeared within one week without any clinical complications.
newtropenija iżolata u ħafifa u iperlattatemija kienet osservata, li spontanjament sparixxiet fi żmien ġimgħa mingħajr kumplikazzjonijiet kliniċi.

reports of fatal hepatic failure as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactataemia/lactic acidosis have been reported with use of ribavirin.
rapporti ta’ insuffiċjenza epatika fatali kif ukoll newropatija periferali, pankreatite, u iperlaktejtimja sintomatika/aċidożi lattika kienu rrappurtati bl-użu ta’ ribavirin.

treatment with nucleoside analogues must be discontinued in the setting of symptomatic hyperlactataemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
it- trattament b’ analogi tan- nukleosidi għandu jitwaqqaf fi ħdan iperlaktatimja sintomatika u aċidożi metabolika/ lattika, epatomegalija progressiva, jew livelli aminotransferase li jogħlew malajr.

treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactataemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
5 it- trattament b’ analogi tan- nukleosidi għandu jitwaqqaf meta sseħħ l- iperlaktejtimja sintomatika u aċidożi lattika/ metabolika, epatomegalija progressiva jew meta l- livelli ta ’ aminotransferase jiżdiedu malajr.

the main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactataemia, hyperlipasaemia).
il - ġrajjiet avversi ewlenin irrapportati huma disturbi ematoloġiċi (anemija, newtropenja), disturbi metaboliċi (iperlaktatimja, iperlipażimja).

42 combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
it- terapija antiretrovirali kombinata ġiet marbuta ma ’ anormalitajiet metaboliċi bħall - ipertriglajseridemija, iperkolesterolemija, reżistenza għall- insulina, ipergliċemija u iperlaktatemija (ara sezzjoni 4. 4).

early symptoms (symptomatic hyperlactataemia) include benign digestive symptoms (nausea, vomiting and abdominal pain), non-specific malaise, loss of appetite, weight loss, respiratory symptoms (rapid and/ or deep breathing) or neurological symptoms (including motor weakness).
sintomi bikrija (l- iperlaktejtimja sintomatika) jinkludu sintomi diġestivi beninji (tqalligħ, rimettar u uġigħ addominali), ħass ħażin mhux speċifiku, nuqqas ta ’ aptit, tnaqqis fil - piż, sintomi respiratorji (nifs mgħaġġel u/ jew qawwi) jew sintomi newroloġiċi (fosthom indeboliment fil- moviment).